Eli Lilly and Company (NYSE: LLY) announced the launch of a new open innovation platform designed to help build the company's pipeline of tomorrow and, from a philanthropic perspective, identify molecules that may have application for treating multi-drug resistant tuberculosis (MDR-TB).

Merck KGaA announced today that it has published a new brochure depicting how the company successfully transforms new ideas into innovative products, services and processes. The brochure concisely presents Merck innovations in pharmaceuticals, chemicals and life sciences that help to improve quality of life.

Sanofi (EURONEXT: SAN and NYSE: SNY) announces that it has successfully priced its offering of USD 1 billion of notes denominated in US dollars, due 2014, bearing interest at an annual rate of 1.20%.

Novartis has presented new Phase III data at the European Respiratory Society (ERS) congress demonstrating the potential for its portfolio of once-daily inhaled therapies to help patients with chronic obstructive pulmonary disease (COPD) to maintain more active and productive lives.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the results of the Phase II study TDM4450g in patients with previously untreated HER2-positive metastatic breast cancer (mBC). The study compared trastuzumab emtansine (also known as T-DM1) to standard treatment with Herceptin (trastuzumab) plus docetaxel chemotherapy.

Novartis announced new data from the pivotal Phase III IMPRES clinical trial showing that the investigational therapy QTI571 (imatinib) significantly improved exercise capacity in patients with pulmonary arterial hypertension (PAH) after 24 weeks compared with placebo[1].

Boehringer Ingelheim announced enrolment has commenced in its TOviTO Phase III clinical trial program. It will investigate tiotropium plus olodaterol in a once-daily fixed-dose combination for the treatment of chronic obstructive pulmonary disease (COPD).